Farmaceutisch Tijdschrift voor België – 99ste jaargang nr. 1 - maart 2019 35
4 Lyu X, Zhao C, Yan Z, et al. Efficacy
of nystatin for the treatment of oral
candidiasis: a systematic review and
meta-analysis. Drug Des Devel Ther
2016:1161-71.
5 Carrillo-Muñoz AJ, Quindós G, Tur C,
et al. In-vitro antifungal activity of
liposomal nystatin in comparison
with nystatin, amphotericin B
cholesteryl sulphate, liposomal
amphotericin B, amphotericin
B lipid complex, amphotericin
B desoxycholate, fluconazole
and itraconazole. J Antimicrob
Chemother 1999;44:397-401.
6 Gunderson SM, Hoffman H, Ernst EJ,
et al. In vitro pharmacodynamic
characteristics of nystatin including
time-kill and postantifungal effect.
Antimicrob Agents Chemother
2000;44:2887-90.
7 Ghannoum MA, Rice LB. Antifungal
Agents : Mode of Action ,
Mechanisms of Resistance, and
Correlation of These Mechanisms
with Bacterial Resistance.
1999;12:501-17.
8 Samaranayake LP, Keung Leung
W., Jin L. Oral mucosal fungal
infections. Periodontolo 2000
2009;49:39-59.
9 Micromedex. Te raadplegen online:
www.micromedexsolutions.com/
(laatst geraadpleegd in juni 2018).
10 Liu W, Guan X, Yu Z, et al. A Drugdrug
Interaction between
Cyclosporine and Nystatin. Clin Ther
2018;40:660–2.
11 U S Food and Drug Administration.
Disponible en ligne : www.fda.gov/
(consulté en juin 2018).
12 Niimi M, Firth NA, Cannon RD.
Antifungal drug resistance of oral
fungi. Odontology 2010;98:15-25.
13 Cannon RD, Chaffin WL.
Oral Colonization by Candida
Albicans. Crit Rev Oral Biol Med
1999;10(3):359-83.
14 Pappas PG, Kauffman CA, Andes DR,
et al. Clinical Practice Guideline for
the Management of Candidiasis:
2016 Update by the Infectious
Diseases Society of America. Clin
Infect Dis 2015;62:e1-50.
15 Nucci M, Anaissie E. Revisiting the
Source of Candidemia: Skin or Gut?
Clin Infect Dis 2001;33:1959-67.
16 BMJ best practice. Disponible en
ligne : https://bestpractice.bmj.com
(consulté en juin 2018).
17 Akpan A, Morgan R. Oral
Candidiasis. Postgrad Med J
2002;78:455-9.
18 Laurent M, Gogly B, Tahmasebi F,
et al. Les candidoses oropharyngées
des personnes âgées. Geriatr
Psychol Neuropsychiatr Vieil
2011;9:21-8.
19 Millsop JW, Fazel N. Oral
candidiasis. Clin Dermatol
2016;34:487-94.
20 Williams D, Lewis M. Pathogenesis
and treatment of oral candidosis.
J Oral Microbiol 2011;3:1-11.
21 Coronado-Castellote L,
Jiménez-Soriano Y. Clinical and
microbiological diagnosis of
oral candidiasis. J Clin Exp Dent
2013;5:279-86.
22 Cuenca‐Estrella M., Verweij PE,
Arendrup MC, et al. ESCMID*
guideline for the diagnosis and
management of Candida diseases
2012: diagnostic procedures. Clin
Microbiol Infect 2012;18:9-18.
23 Rautemaa R, Ramage G. Oral
candidosis Clinical challenges of a
biofilm disease. Crit Rev Microbiol
2011;37:328-36.
24 Garcia-Cuesta C, Sarrion-Perez M,
Bagan J. Current treatment of oral
candidiasis: A literature review. J
Clin Exp Dent 2014;6:e576-82.
25 Cross LJ, Williams DW, Sweeney CP,
et al. Evaluation of the recurrence
of denture stomatitis and Candida
colonization in a small group of
patients who received itraconazole.
Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2004;97:351-8.
26 Grimoud AM, Lodter JP, Marty N,
et al. Improved oral hygiene and
Candida species colonization level
in geriatric patients. Oral Dis
2005;11:163-9.
27 Gøtzsche PC, Johansen HK.
Nystatin prophylaxis and treatment
in severely immunodepressed
patients. Cochrane Database Syst
Rev 2014;2017.
28 Melkoumov A, Goupil M,
Louhichi F, et al. Nystatin
nanosizing enhances in vitro and
in vivo antifungal activity against
Candida albicans. J Antimicrob
Chemother 2013;68:2099-105.
29 Sklenář Z, Ščigel V, Horáčkova K,
et al. Compounded preparations
with nystatin for oral and
oromucosal administration.
Acta Pol Pharm - Drug Res
2013;70:759-62.
30 Martín MJ, Calpena AC,
Fernández F, et al. Development
of alginate microspheres as
nystatin carriers for oral mucosa
drug delivery. Carbohydr Polym
2015;117:140-9.
31 Llabot JM, Manzo RH, Allemandi DA.
Double-layered mucoadhesive
tablets containing nystatin. AAPS
PharmSciTech 2002;3.
32 Federaal Agentschap
voor Geneesmiddelen en
Gezondheidsproducten (FAGG).
Beschikbaar online: www.afmps.
be/fr (laatst geraadpleegd in
juni 2018).
33 Therapeutisch Magistraal
Formularium. 3e editie. Beschikbaar
online: www.tmf-ftm.be/ (laatst
geraadpleegd in juni 2018).
34 Morgan R, Tsang J, Harrington N,
et al. Survey of hospital doctors’
attitudes and knowledge of oral
conditions in older patients.
Postgrad Med J 2001;77:392-4.
35 Belgisch Centrum voor
Farmacotherapeutische Informatie
(BCFI). Beschikbaar online:
http://www.bcfi.be/nl (laatst
geraadpleegd in juni 2018).
36 Hamdy RF, Zaoutis TE, Seo SK.
Antifungal stewardship
considerations for adults and
pediatrics. Virulence 2016;8:1-15.
Onderzoek Étude
/www.afmps
/
/bestpractice.bmj.com
/
/
/nl